Industry News

• Streck signs distribution agreement with Ngaio Diagnostics  Streck and Ngaio Diagnostics, a distributor that represents highly successful and globally recognized clinical and molecular biology brands in the New Zealand market, have signed a distribution agreement for Streck’s cell stabilization and molecular products.
  May 26, 2017  
• Merit Medical announces appointment of new director  Merit Medical Systems announced it has appointed Thomas Gunderson to serve as a director of the Company. Gunderson recently retired from a 24-year career at Piper Jaffray where he covered numerous companies as a Senior Research Analyst for Medical Technology.
  May 26, 2017  
• EnWave announces 2017 second quarter interim financial results  EnWave reported revenue of $4,183,000, and a consolidated net loss of $779,000 for the second quarter of fiscal year 2017. Non-cash items included in the consolidated net loss were $339,000 of stock based compensation expense and $220,000 of amortization expense related to intangible assets.
  May 26, 2017  
• SteadyMed raises additional capital from key institutional shareholder  SteadyMed announced that one of its largest institutional shareholders has exercised warrants to purchase additional shares of the Company received in conjunction with the first tranche of SteadyMed’s third quarter 2016 private placement. SteadyMed received additional proceeds totaling $5 million.
  May 26, 2017  
• Yield10 Bioscience announces 1-for-10 reverse stock split  Yield10 Bioscience announced it will effect a 1-for-10 reverse stock split of its common stock. The 1-for-10 reverse stock split will be effective as of the close of business on Friday, May 26, 2017 and the Company's common stock will begin trading on a split-adjusted basis on Tuesday, May 30, 2017.
  May 26, 2017  
• Aerie Pharmaceuticals raises $125 million in ATM sales and upsized follow-on offering  Aerie Pharma announced it has priced its registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $53.75 per share. The offering was upsized by $25 million. Total gross proceeds are expected to be $125 million.
  May 26, 2017  
• Zika infections could be factor in more pregnancies  Zika virus infection passes efficiently from a pregnant monkey to its fetus, spreading inflammatory damage throughout the tissues that support the fetus and developing nervous system, suggesting the virus poses a wider threat in human pregnancies than generally appreciated, scientists have found.
  May 25, 2017  Chris Barncard
• Lion Biotechnologies announces departure of CFO  Lion Biotechnologies announced that Gregory Schiffman, CFO, has decided to leave the company for personal reasons, preventing him from commuting from his residence in Portland to the Company's corporate headquarters in San Carlos, CA. A search for a new CFO is underway through a recruitment agency.
  May 25, 2017  
• Health Canada grants approval for Ocaliva(TM) (obeticholic acid) for reatment of PBC  Intercept Pharmaceuticals announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for treatment of primary biliary cholangitis, when used in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.
  May 25, 2017  
• Aerie Pharmaceuticals announces public offering of common stock  Aerie Pharmaceuticals announced it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Aerie intends to use the net proceeds to fund expansion of its commercialization programs in North America for both RhopressaTM and RoclatanTM.
  May 25, 2017  

   (next 10 articles)